JP2024514087A - 抗ｃｔｌａ４抗体を用いたがんの治療方法 - Google Patents

抗ｃｔｌａ４抗体を用いたがんの治療方法 Download PDF

Info

Publication number
JP2024514087A
JP2024514087A JP2023559990A JP2023559990A JP2024514087A JP 2024514087 A JP2024514087 A JP 2024514087A JP 2023559990 A JP2023559990 A JP 2023559990A JP 2023559990 A JP2023559990 A JP 2023559990A JP 2024514087 A JP2024514087 A JP 2024514087A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
hvr
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023559990A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514087A5 (https=
Inventor
ピーター ペイチー ルオ，
ギジョン リュウ，
ホア チャン ゴン，
ソンマオ チョン，
Original Assignee
アダジーン プライベート リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アダジーン プライベート リミテッド filed Critical アダジーン プライベート リミテッド
Publication of JP2024514087A publication Critical patent/JP2024514087A/ja
Publication of JP2024514087A5 publication Critical patent/JP2024514087A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2023559990A 2021-03-28 2022-03-28 抗ｃｔｌａ４抗体を用いたがんの治療方法 Pending JP2024514087A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163167111P 2021-03-28 2021-03-28
US63/167,111 2021-03-28
PCT/US2022/022198 WO2022212286A1 (en) 2021-03-28 2022-03-28 Methods for treating cancer using anti-ctla4 antibodies

Publications (2)

Publication Number Publication Date
JP2024514087A true JP2024514087A (ja) 2024-03-28
JP2024514087A5 JP2024514087A5 (https=) 2025-04-04

Family

ID=83456928

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023559990A Pending JP2024514087A (ja) 2021-03-28 2022-03-28 抗ｃｔｌａ４抗体を用いたがんの治療方法

Country Status (5)

Country Link
US (1) US20240209091A1 (https=)
EP (1) EP4313147A4 (https=)
JP (1) JP2024514087A (https=)
CN (1) CN117794569A (https=)
WO (1) WO2022212286A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4611905A1 (en) * 2022-11-05 2025-09-10 Adagene Pte. Ltd. Methods for treating cancer using anti-ctla4 antibody in combination with pembrolizumab
WO2024216179A1 (en) * 2023-04-13 2024-10-17 Adagene Pte. Ltd. Methods for treating cancer using activatable anti-ctla4 antibody in combination with pembrolizumab

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009518446A (ja) * 2005-12-07 2009-05-07 メダレックス インコーポレーティッド Ｃｔｌａ−４抗体投与量漸増レジメン
WO2019149281A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
WO2021228178A1 (en) * 2020-05-13 2021-11-18 Adagene Ag Compositions and methods for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014337063A1 (en) * 2013-10-18 2016-05-19 Adaptive Biotechnologies Corp. Predicting patient responsiveness to immune checkpoint inhibitors
JPWO2020149026A1 (ja) * 2019-01-04 2021-11-18 国立大学法人京都大学 Ｐｄ−１シグナル阻害剤含有薬剤による治療有効性の予測及び／又は判定マーカー
KR20210146348A (ko) * 2019-03-28 2021-12-03 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009518446A (ja) * 2005-12-07 2009-05-07 メダレックス インコーポレーティッド Ｃｔｌａ−４抗体投与量漸増レジメン
WO2019149281A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
WO2021228178A1 (en) * 2020-05-13 2021-11-18 Adagene Ag Compositions and methods for treating cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"A phase 1b/2 study of ADG116, ADG116 combined with anti-PD-1antibody or anti-CD137 antibody in solid", CLINICALTRIALS.GOV, ID NCT04501276, RECORD HISTORY, VER. 2, JPN6026007574, 15 October 2020 (2020-10-15), ISSN: 0005807966 *
ANNALS OF ONCOLOGY, vol. vol. 32 Supplement 7, JPN6026007573, December 2021 (2021-12-01), pages 1436 - 1437, ISSN: 0005807968 *
JOURNAL OF IMMUNO THERAPY OF CANCER, vol. vol. 7 (supplment 1), JPN6026007572, 2019, pages 151 - 152, ISSN: 0005807967 *

Also Published As

Publication number Publication date
EP4313147A4 (en) 2025-03-19
US20240209091A1 (en) 2024-06-27
WO2022212286A1 (en) 2022-10-06
EP4313147A1 (en) 2024-02-07
CN117794569A (zh) 2024-03-29

Similar Documents

Publication Publication Date Title
US12378319B2 (en) Anti-CD137 molecules and use thereof
TWI652345B (zh) 與４-１ｂｂ結合之分子類
EP3328425B1 (en) Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer
JP2021507877A (ja) Ｃｄ１３７リガンドを抗ｃｄ１３７抗体を用いた治療向けのバイオマーカーとして使用するための方法
WO2021228178A1 (en) Compositions and methods for treating cancer
US20240209091A1 (en) Methods for treating cancer using anti-ctla4 antibodies
WO2020244574A1 (en) Anti-cd137l antibodies and methods of using same
WO2024097896A1 (en) Methods for treating cancer using anti-ctla4 antibody in combination with pembrolizumab
WO2021227326A1 (en) Compositions and methods for treating cancer
CA3072384C (en) Anti-cd137 molecules and use thereof
WO2024050429A2 (en) Methods for treating cancer using anti-ctla4 antibodies
CA3236735A1 (en) Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate
HK1247848B (en) Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250327

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260303